



## APPENDIX OF AMENDMENTS

26. (**Twice** Amended) An influenza antigen comprising a fusion product, said fusion product comprising

(i) an **immunogenic** extracellular part of **(a)** an M2 membrane protein of a human influenza A virus, [or of a similar integral membrane] **(b) an NB** protein of a human influenza B [or C] virus, **or (c) a CM2 protein of a human influenza C virus,** and

(ii) a presenting carrier [,

wherein said extracellular part of the M2 membrane protein contains all or part of SEQ ID NO:1, 2 or 3].

32. (**Twice** Amended) The influenza antigen of claim 31, wherein the presenting carrier comprises an epitope [of] **recognized by** an influenza-specific T helper cell or cytotoxic T cell.

46. (**Twice** Amended) An influenza antigen obtained by the following steps:

providing a nucleic acid construct that encodes a fusion product, said fusion product comprising (i) an **immunogenic** extracellular part of **(a)** an M2 membrane protein of a human influenza A virus, [or of a similar integral membrane protein of] **(b) an NB protein of** a human influenza B [or C] virus, **or (c) a CM2 protein of a human**

**influenza C virus**, and (ii) a presenting [carrier] **peptide**], wherein said extracellular part of the M2 membrane protein contains all or part of SEQ ID NO:1, 2 or 3];

introducing the nucleic acid construct into an acceptor cell;

culturing the acceptor cell under conditions that allow expression of the fusion product; and

optionally isolating the fusion product from the acceptor cell or its culture medium,

thereby obtaining an influenza antigen comprising the fusion product.

52. **(Amended)** The influenza [antigen] **vaccine** of claim [26] **35**, wherein the influenza [antigen] **vaccine** comprises a cytokine.

53. **(Amended)** The influenza [antigen] **vaccine** of claim [26] **35**, wherein the influenza [antigen] **vaccine** comprises a vaccine adjuvant that is not [Freud's] **Freund's** adjuvant.

54. **(Amended)** An influenza antigen for an animal species comprising a fusion product, said fusion product comprising

(i) an **immunogenic** extracellular part of **(a)** an M2 membrane protein of an influenza A virus **or (b) an NB protein of an influenza B virus** of said animal species[, or of a similar integral membrane protein of an influenza B or C virus of said animal species]; and

(ii) a presenting carrier.